Q2 FY2026
Filed Aug 11, 2026AUCATZYL® net product revenue reached $45.7 million in Q2 2026, gross margin rose to 55%, and Autolus increased FY 2026 net product revenue guidance to $140 million to $150 million.
AUCATZYL revenue increased 119% year-over-year to $45.7 million and rose from $26.2 million in the prior quarter, while gross margin improved to 55% from 6% in Q1 2026. The company raised full-year revenue guidance and secured a credit facility with $75 million funded at close, although it remained loss-making and selling, general and administrative expenses increased.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, netother | $45,672 | – | 119% |
| License revenueother | 17 | – | – |
| Total revenue, netother | 45,689 | – | – |
| Cost of salesother | (20,468) | – | – |
| Gross marginother | 55% | – | – |
| Research and development expenses, netother | (27,898) | – | – |
| Selling, general and administrative expensesother | (41,161) | – | – |
| Loss from operationsother | (43,838) | – | – |
| Total other income (expenses), netother | 5,192 | – | – |
| Income tax expenseother | (465) | – | – |
| Net lossother | (39,111) | – | – |
| Total other comprehensive income (loss), net of taxother | 526 | – | – |
| Total comprehensive lossother | $(38,585) | – | – |
| Basic and diluted net loss per ordinary shareother | $(0.15) | – | – |
| Weighted-average basic and diluted ordinary sharesother | 266,158,829 | – | – |
| Six-month product revenue, netother | $71,890 | – | – |
| Six-month license revenueother | 17 | – | – |
| Six-month total revenue, netother | 71,907 | – | – |
| Six-month cost of salesother | (45,036) | – | – |
| Six-month research and development expenses, netother | (49,108) | – | – |
| Six-month selling, general and administrative expensesother | (81,114) | – | – |
| Six-month loss from operationsother | (103,351) | – | – |
| Six-month total other income (expenses), netother | (6,030) | – | – |
| Six-month income tax expenseother | (1,328) | – | – |
| Six-month net lossother | (110,709) | – | – |
| Six-month total other comprehensive income (loss), net of taxother | (745) | – | – |
| Six-month total comprehensive lossother | $(111,454) | – | – |
| Six-month basic and diluted net loss per ordinary shareother | $(0.42) | – | – |
| Six-month weighted-average basic and diluted ordinary sharesother | 266,151,170 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| AUCATZYL® (obecabtagene autoleucel; obe-cel)Increasing product demand within existing treatment centers, expansion into new centers, and contribution from UK sales in the second quarter of launch in that market. | $45.7 million | – | 119% |
FY 2026 outlook
- Revenue$140 million to $150 million
- Gross margin65-70%
- NoteAutolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations into Q2 2028.
What drove it
- Net revenue growth was primarily driven by increasing product demand within existing treatment centers, expansion into new centers, and UK sales.
- Gross-margin improvement was primarily driven by reduced manufacturing cost per batch from increased volumes and operational efficiency initiatives, plus lower inventory reserves and write-offs compared with the prior-year period.
- Research and development expense increased because of clinical-trial and clinical-manufacturing supply costs, partially offset by lower salaries and other employment-related costs.
- Selling, general and administrative expense increased due to salaries, other employment-related costs and professional fees supporting US and UK commercialization, as well as termination-related expenses.
- The April 2026 efficiency initiative included a workforce reduction affecting approximately 13% of the existing overall workforce and is expected to reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027.
Concerns
- Net loss was $39.1 million for the three months ended June 30, 2026.
- Selling, general and administrative expenses increased to $41.2 million from $30.3 million in the prior-year period.
- Research and development expenses increased to $27.9 million from $27.4 million in the prior-year period.
- Cash, cash equivalents and marketable securities declined to $201.6 million at June 30, 2026, from $229.4 million at March 31, 2026.
- Access to the additional $150 million under the credit facility is contingent on achievement of certain pre-specified revenue milestones.
What to watch
- Longer-term follow-up data from the CARLYSLE trial in severe refractory systemic lupus erythematosus are expected by year-end 2026.
- Initial clinical data from the ALARIC Phase 1 trial in light-chain amyloidosis are expected by year-end 2026.
- Initial clinical data from the BOBCAT Phase 1 trial in progressive MS are planned for Q1 2027, with a larger data set with longer follow up planned for 2H 2027.
- Phase 2 data from the CATULUS trial in pediatric r/r B-ALL are expected by year-end 2027.
- Phase 2 data from the LUMINA trial in lupus nephritis are expected in 2028.
- Continued AUCATZYL adoption across existing and new treatment centers, UK sales contribution, and progress toward the stated 65-70% peak estimate for adult ALL margins.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities at June 30, 2026, totaled $201.6 million, as compared to $229.4 million at March 31, 2026.
- Cash and cash equivalents were $ 171,414 at June 30, 2026, compared with $ 104,132 at December 31, 2025.
- Marketable securities - Available-for-sale debt securities were $ 30,216 at June 30, 2026, compared with $ 196,578 at December 31, 2025.
- Total current assets were $ 336,091 at June 30, 2026, compared with $ 435,915 at December 31, 2025.
- Total assets were $ 493,226 at June 30, 2026, compared with $ 589,068 at December 31, 2025.
- Total current liabilities were $ 68,790 at June 30, 2026, compared with $ 73,440 at December 31, 2025.
- Total liabilities were $ 418,387 at June 30, 2026, compared with $ 410,939 at December 31, 2025.
- Total shareholders' equity was $ 493,226 at June 30, 2026, compared with $ 589,068 at December 31, 2025.
- An initial $75 million principal amount of notes was issued to Perceptive on July 30, 2026.
- An additional $25 million in aggregate principal amount will be available at Autolus’ option for up to six months post-closing.
- An additional $150 million in aggregate principal amount of subsequent capital may become available in separate tranches upon achievement of certain pre-specified revenue milestones.
Analysis
Autolus reported a strong commercial quarter for AUCATZYL. Net product revenue was $45.7 million, compared with $20.9 million in the prior-year period and $26.2 million in the three months ending March 31, 2026. Management attributed the revenue increase to higher demand at existing treatment centers, new centers coming online, and UK sales in the second quarter of launch in that market. The company raised FY 2026 AUCATZYL net product revenue guidance to $140 million to $150 million from between $120 million to $135 million.
The principal financial change was the improvement in gross margin to 55% in Q2 2026 from 6% in Q1 2026. Cost of sales declined to $20.5 million from $24.4 million in the prior-year period even as product revenue increased. The company attributed the margin improvement to lower manufacturing cost per batch from higher volumes and efficiency initiatives, alongside lower inventory reserves and write-offs. Management stated an expectation for improvement over time toward a 65-70% peak estimate for adult ALL margins.
The company remained loss-making despite the revenue and margin progress. Loss from operations was $43.8 million and net loss was $39.1 million, compared with $61.2 million and $47.9 million, respectively, in the prior-year quarter. R&D expense increased to $27.9 million due to clinical-trial and clinical-manufacturing supply costs. SG&A increased to $41.2 million, reflecting commercialization support in the US and UK plus termination-related costs from the April 2026 operational-efficiency initiative.
Liquidity was supported by $201.6 million of cash, cash equivalents and marketable securities at June 30, 2026, although this was down from $229.4 million at March 31, 2026. Subsequent to quarter-end, Autolus issued an initial $75 million principal amount under a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. The company said the combined first and second tranches total $100 million and, together with anticipated AUCATZYL net revenues, are expected to fund operations into Q2 2028.
Pipeline milestones remain important alongside commercialization. The company expects CARLYSLE and ALARIC updates by year-end 2026, initial BOBCAT data in Q1 2027, CATULUS Phase 2 data by year-end 2027, and LUMINA Phase 2 data in 2028. Execution priorities are sustaining AUCATZYL demand growth, translating volume into further gross-margin improvement, managing commercialization expenses, and meeting the revenue milestones associated with subsequent credit-facility tranches.
Management, verbatim
In the second quarter we achieved substantial sales growth in the ongoing AUCATZYL launch, driven by physician enthusiasm and expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online.
Dr. Christian Itin, Chief Executive Officer of Autolus
The increased product volumes, combined with the ongoing operational efficiency initiatives announced in April, together drove a significant step up in gross margin. We expect improvement over time towards our peak estimate for adult ALL margins of 65-70%.
Dr. Christian Itin, Chief Executive Officer of Autolus
We see adoption of AUCATZYL in adult r/r B-ALL as a key near-term value driver. Longer-term, we believe there are meaningful opportunities to expand into new indications to continue driving scalable growth by leveraging obe-cel’s favorable profile and Autolus’ proven manufacturing and commercial capabilities.
Dr. Christian Itin, Chief Executive Officer of Autolus
Not in the filing
stated, not guessed- GAAP or non-GAAP accounting basis was not explicitly stated in the provided filing text.
- Non-GAAP revenue, gross margin, operating income, net income, EPS, and reconciliations were not reported.
- Prior-year numerical gross margin for Q2 2025 was not reported; the filing stated only that gross margin was negative in all prior quarters in 2025.
- Prior-quarter total revenue, cost of sales, operating expenses, operating loss, net loss, and EPS were not reported.
- Operating cash flow and free cash flow were not reported.
- A numerical debt balance at June 30, 2026 was not reported.
- Share repurchases, dividends, and other shareholder capital-return activity were not reported.
- Guidance for operating expenses and tax rate was not reported.
- A prior earnings release outlook section was not provided, so no reported results were compared against prior guidance.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.